Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases

R. Loch, Hongzhi Wang, Alex Perálvarez‐Marín, Philipp Berger, Henrietta M. Nielsen, Angeliki Chroni, Jinghui LuoComputational 2023 · DOI

TL;DR

This review synthesizes the complex cross-interactions between Apolipoprotein E (ApoE) isoforms and various amyloid proteins, highlighting their crucial, yet often underappreciated, roles in neurodegenerative diseases. Understanding these interactions is vital for developing more effective therapeutic strategies beyond targeting single amyloid proteins.

What Problem Does This Paper Address?

Neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS are a growing global burden, characterized by the abnormal accumulation of amyloid proteins. While Apolipoprotein E (ApoE) is a known risk factor, particularly the ApoE4 isoform, the intricate molecular interplay between ApoE and the diverse array of amyloid proteins involved in these diseases remains poorly connected and understood. Existing therapeutic approaches targeting single amyloid proteins have shown limited success, suggesting that a more holistic view, encompassing the complex network of interactions, is needed to unravel disease pathogenesis and develop effective treatments. This paper aims to bridge this gap by consolidating current knowledge on ApoE-amyloid protein interactions.

Methods

This paper is a comprehensive review and synthesis of existing research. It does not present novel experimental data or computational methods. Instead, it draws upon a vast body of published literature, including experimental studies (biophysical, biochemical, cell-based, and animal models) and theoretical/computational analyses, to connect and clarify the interactions between ApoE isoforms and various amyloid proteins. The authors analyze these interactions across different disease contexts and propose potential interaction mechanisms.

Datasets

Not discussed in the paper. This is a review article synthesizing existing literature.

Key Insights and Ideas

  • ApoE is a central player, not just a risk factor: ApoE isn't merely a passive bystander or risk factor; its isoforms actively modulate the generation, aggregation, clearance, and cellular fate of multiple amyloid proteins.
  • Isoform-specific effects are critical: The subtle differences between ApoE2, ApoE3, and ApoE4 (due to single amino acid variations) lead to distinct structural conformations and, consequently, isoform-specific roles in disease pathogenesis. ApoE4, in particular, often exhibits detrimental effects.
  • Amyloid proteins are a diverse but interconnected family: Over 30 amyloid proteins exist, sharing structural and toxicological similarities, suggesting a common "interactome" with other cellular components, including ApoE.
  • Lipid interactions are key: ApoE's primary role in lipid homeostasis is intrinsically linked to its interactions with amyloid proteins. Lipidation state and cholesterol levels significantly influence these cross-interactions, often occurring within lipid rafts.
  • Phase separation is a novel locus of interaction: Membrane-less organelles formed through phase separation are emerging as critical sites where ApoE and amyloid proteins can co-localize and interact, potentially driving aggregation.
  • Therapeutic strategies need to be multimodal: The failure of single-target therapies highlights the need to consider the complex network of ApoE-amyloid interactions, suggesting that therapies might need to address multiple aspects of this interplay or consider ApoE itself as a therapeutic target.

Key Results

The paper does not present quantitative results in the traditional sense, as it is a review. However, it consolidates findings that demonstrate:

  • ApoE isoforms differentially affect Aß and tau: ApoE4, for instance, is linked to increased Aß production and can exacerbate tau pathology, while ApoE3 may have protective roles through stabilizing tau.
  • ApoE influences other amyloid proteins: Interactions with alpha-synuclein (Parkinson's), prion proteins (TSEs), IAPP (Type 2 Diabetes), SOD1 (ALS), and TDP-43 (ALS/AD) are described, often with ApoE4 showing increased risk or detrimental effects.
  • Proposed interaction mechanisms: The authors propose that ApoE isoforms, particularly ApoE4, can adopt molten globule states that facilitate cross-interactions with amyloid proteins, driven by energy landscapes and occurring in specific cellular loci like lipid membranes and phase-separated droplets.

Limitations and Future Work

The authors acknowledge several limitations and areas for future research:

  • In vitro vs. in vivo discrepancies: Many studies are conducted in vitro, and extrapolating these findings to complex in vivo physiological conditions remains challenging due to differences in environment, protein modifications, and the presence of other interacting molecules.
  • Underexplored interactions: Data on ApoE interactions with some amyloid proteins (e.g., TTR, ẞ2m, Prolactin, AA) are scarce, requiring further investigation.
  • Role of post-translational modifications: The impact of ApoE lipidation, sialylation, oxidation, and glycation states on its interactions with amyloids is not fully understood and requires more research.
  • Optimal ApoE concentration and lipidation: A clear understanding of the isoform-dependent optimal range for ApoE concentration and lipidation state for maintaining homeostasis is still lacking.
  • Therapeutic development: While ApoE-based therapies are promising, challenges remain in targeting ApoE's multiple functions. Future work should focus on understanding normal ApoE functions, the precise mechanisms of cross-interactions under stress, and reconciling in vitro and in vivo findings for effective therapeutic design. Addressing the interplay with chronic inflammation, oxidative stress, and the microbiome is also crucial.

Summary updated

Abstract

Three common Apolipoprotein E isoforms, ApoE2, ApoE3, and ApoE4, are key regulators of lipid homeostasis, among other functions. Apolipoprotein E can interact with amyloid proteins. The isoforms differ by one or two residues at positions 112 and 158, and possess distinct structural conformations and functions, leading to isoform-specific roles in amyloid-based neurodegenerative diseases. Over 30 different amyloid proteins have been found to share similar characteristics of structure and toxicity, suggesting a common interactome. The molecular and genetic interactions of ApoE with amyloid proteins have been extensively studied in neurodegenerative diseases, but have not yet been well connected and clarified. Here we summarize essential features of the interactions between ApoE and different amyloid proteins, identify gaps in the understanding of the interactome and propose the general interaction mechanism between ApoE isoforms and amyloid proteins. Perhaps more importantly, this review outlines what we can learn from the interactome of ApoE and amyloid proteins; that is the need to see both ApoE and amyloid proteins as a basis to understand neurodegenerative diseases.
BibTeX
@inproceedings{loch2023cross,
  author = {R. Loch and Hongzhi Wang and Alex Perálvarez‐Marín and Philipp Berger and Henrietta M. Nielsen and Angeliki Chroni and Jinghui Luo},
  title = {{Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases}},
  booktitle = {Computational},
  year = {2023},
  doi = {10.1016/j.csbj.2023.01.022},
}
Figure